XML 69 R39.htm IDEA: XBRL DOCUMENT v3.20.2
Equity (Tables)
 12 Months Ended
Dec. 31, 2019
Share-based Payment Arrangement [Abstract]  
Stock options activity
A summary of stock option activity as of December 31, 2019, and changes during the year then ended are presented below:
 
Number of
Shares
 
Weighted-
Average
Exercise
Price
 
Weighted-
Average
Remaining
Contractual
Term
(in years)
 
Aggregate
Intrinsic
Value
Outstanding at January 1, 2019
3,697,147

 
$
4.59

 
 
 
 
Granted
—

 
—

 
 
 
 
Exercised
(150,000
)
 
0.72

 
 
 
 
Unvested options forfeited
—

 
—

 
 
 
 
Vested options expired
(661,813
)
 
6.21

 
 
 
 
Outstanding at December 31, 2019
2,885,334

 
4.42

 
2.73
 
$
9,191,697

Exercisable at December 31, 2019
2,885,334

 
$
4.42

 
2.73
 
$
9,191,697
Option Modification Assumptions
2019 Option Modification
Expected volatility
65% - 95%
Expected life (in years)
0.28 - 5.12
Expected dividend yield
—
Risk-free interest rate
1.56% - 2.02%
Restricted stock awards roll forward
Following is summary information for restricted stock awards for the year ended December 31, 2019. Shares vest over a one to three year period in equal annual increments and require continuous service.
As of December 31, 2019, there was approximately $11.4 million of total unrecognized stock-based compensation related to non-vested restricted stock.  That expense is expected to be recognized over a weighted-average period of 1.8 years, which approximates the remaining vesting period of these grants. All shares noted below as unvested are considered issued and outstanding at December 31, 2019.
 
 
Number of
Shares
 
Weighted-Average Grant Date
Fair Value
Unvested at January 1, 2019
 
2,999,135

 
$
8.83

Granted
 
3,084,875

 
3.35

Vested
 
(1,474,998
)
 
8.58

Forfeited
 
(1,084,971
)
 
5.31

Unvested at December 31, 2019
 
3,524,041

 
$
5.21
Allocation of share-based compensation
For the years ended December 31, 2019, 2018, and 2017 the Company recognized share-based compensation as follows (in thousands):
 
 
Years Ended December 31,
 
2019
 
2018
 
2017
 
 
 
 
 
 
Cost of sales
$
477

 
$
705

 
$
539

Research and development
265

 
584

 
604

Selling, general and administrative
11,322

 
13,479

 
20,052

Total share-based compensation
$
12,064

 
$
14,768

 
$
21,195

Income tax benefit
(3,081
)
 
(3,803
)

(5,345
)
Total share-based compensation, net of tax benefit
$
8,983

 
$
10,965

 
$
15,850